

Special Issue

SARS-CoV-2 Infection and COVID-19 Vaccination: Exploring Pathogenesis, Immune Response and Immunopathogenic Complications

Message from the Guest Editors

The COVID-19 pandemic has led to a significant global health burden, with SARS-CoV-2 infection causing a wide spectrum of complications, ranging from acute inflammatory syndromes to long-term sequelae. While vaccination has played a critical role in controlling the spread of the virus and reducing severe disease outcomes, rare adverse events, such as myocarditis, thrombosis, and autoimmune reactions, have been reported. Understanding the immunopathogenic mechanisms behind these complications is essential for improving treatment strategies and vaccine safety. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:

- **Complications of SARS-CoV-2 infection** (e.g. multisystem inflammatory syndrome, long COVID-19)
- **Adverse events following COVID-19 vaccination** (e.g. myocarditis, thrombosis, autoimmune manifestations)
- **Immunopathogenesis of infection- and vaccine-related complications**
- **Viral persistence and its impact on the immune response**
- **Risk factors and predictive markers for severe complications**
- **Therapeutic and preventive strategies for managing these complications**

Guest Editors

Dr. Ronaldo B. Martins

Dr. Tamara Rodrigues

Dr. Flavio Protasio Veras

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/234649

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).